This Pregabalin market analysis gives an examination of a range of segments that are relied upon to witness the quickest development amid the estimate forecast frame. The company profiles of all the key players and brands that are dominating the Pregabalin market with moves like product launches, joint ventures, mergers and acquisitions which in turn is affecting the sales, import, export, revenue and CAGR values are mentioned in the report. A complete discussion about numerous market related topics in this Pregabalin market research report is sure to aid the client in studying the market on competitive landscape.

The data and information collected with the research is generally quite a huge and is in a complex form. However, such intricate market insights are turned into simpler version with the help of proven tools and techniques to provide it to the end users. Estimations of CAGR values, market drivers and market restraints helps businesses decide upon several strategies. The use of proven tools such as SWOT analysis and Porter’s Five Forces analysis are very helpful in creating such a top-notch Pregabalin market research report. With the use of few steps or the combination of several steps, the process of generating Pregabalin market report is initiated with the expert advice.

Data Bridge Market Research analyses that the pregabalin market was valued at USD 769.47 million in 2021 and is expected to reach USD 596.65 billion by 2029, registering a CAGR of 3.53% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get a Sample Research Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pregabalin-market

Pregabalin is an anticonvulsant medication that can be used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. It works by reducing the pain signals delivered by injured nerves throughout the body. As per the International Association of the Study of Pain's Global Year against Neuropathic Pain 2014-2015 study, approximately 7% to 8% of adults suffer from chronic pain with neuropathic characteristics. Furthermore, the patent expiration of Pfizers' Lyrica (Pregabalin) in 2018 is expected to boost generic manufacturing manufacturers' market share in the U.K.

Key Growth Drivers:

  • Rise in the prevalence of epilepsy

The surging prevalence of epilepsy is a major factor driving the pregabalin market's growth rate during the forecast period of 2022-2029. According to the World Health Organization (WHO), an estimated 50 million people are living with epilepsy globally in 2019, with up to 75 percent of them living in resource-poor countries with little or no access to treatment or medical services. Furthermore, approximately 80% of people with epilepsy live in low- and middle-income nations. In the treatment of epilepsy, pregabalin stops seizures by reducing aberrant electrical activity in the brain.

  • Extensive application of Lyrica

The growing application of Lyrica is anticipated to propel the market's growth rate. Lyrica (pregabalin) is a fibromyalgia drug approved by the US Food and Drug Administration. Fibromyalgia is a chronic illness that causes long-term, widespread muscle pain and soreness and sleeping difficulties and exhaustion. Lyrica is a drug used to treat nerve signals. Fibromyalgia affects over 4 million individuals in the United States, or about 2% of the adult population, according to the Centers for Disease Control and Prevention (CDC). The aetiology of fibromyalgia is unknown, but it can be effectively treated and managed. Lyrica has long been used to treat nerve pain in shingles or diabetic neuropathy patients. The drug Lyrica is also used to treat partial seizures.

The report outlines the involvement of key players, including:

Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Zydus Cadila (India), Lupin (India), Amneal Pharmaceuticals LLC. (US), Cipla Inc. (US), Torrent Pharmaceuticals Ltd. (India), Aurobindo Pharma (India), Glenmark Pharmaceuticals Limited (India), Medley Pharmaceuticals Ltd. (India), Genesis Biotec Inc. (India), Biomax Pharmaceutical Company (UK), ZCL Chemicals Ltd. (India), Olon S.p.A. (Italy), HIKAL Ltd. (India)

Key Market Segmentation

Dosage Forms (Oral Capsule, Oral Solution, Oral Tablet, Extended Release), Application (Epilepsy, Neuropathic Pain, Anxiety Disorder, Others), Drug Class (Fibromyalgia Agents, Anticonvulsants, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Know More about This Premium Research Report @ https://www.databridgemarketresearch.com/reports/global-pregabalin-market

 

Browse More Reports:

https://www.databridgemarketresearch.com/reports/global-molecular-biology-kits-and-reagent-market

https://www.databridgemarketresearch.com/reports/global-electrostatic-live-cell-encapsulation-market

https://www.databridgemarketresearch.com/reports/global-pernicious-anemia-testing-market

https://www.databridgemarketresearch.com/reports/global-chromatography-in-cannabis-testing-market

https://www.databridgemarketresearch.com/reports/global-dental-intraoral-radiology-equipment-market

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Contact Us

US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com